More on RCKT
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $2.31 |
|
|||
| Open | $2.27 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $2.29 | ||||
| Day Low | $2.17 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 1,601,102 | ||||
- Rocket Pharmaceuticals to Participate in Chardan’s 10th Annual Healthcare Conference
- Goldman Sachs Upgrades Rocket Pharmaceuticals (RCKT) to Neutral
- Rocket Pharmaceuticals updates RP-A501 Danon disease trial data
- Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar
- Rocket Pharmaceuticals (RCKT) Reiterated at Overweight by Cantor Fitzgerald After Update on RP-A501
- Rocket Pharmaceuticals (RCKT) PT Lowered to $2.95 at Jefferies
- Form 8-K ROCKET PHARMACEUTICALS, For: Sep 30
- Rocket Pharmaceuticals secures $150M credit facility with Hercules Capital
- Rocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital
- Needham Upgrades Rocket Pharmaceuticals (RCKT) to Buy
Entities mentioned with RCKT
- FDA | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Definitive Agreement | View Related Stories »
- Earnings | View Related Stories »
- JPMorgan | View Related Stories »
- Cowen & Co | View Related Stories »
- Show More...
